Sacubitril 24mg + Valsartan 26mg Tablet (Sacustep 50) in PCD Pharma Franchise in Delhi

Sacubitril 24mg + Valsartan 26mg Tablet (Sacustep 50) in Pharmaceutical Manufacturing Company in Baddi

Sacubitril 24mg + Valsartan 26mg Tablet (Sacustep 50) in Cardiac Pharma Franchise in Pune

Sacubitril 24mg + Valsartan 26mg Tablet (Sacustep 50) in Pharma Distributors & Suppliers in Chennai

Sacubitril 24mg + Valsartan 26mg Tablet (Sacustep 50) in Pharma Export Company in Ahmedabad
Sacubitril 24mg + Valsartan 26mg Tablet (Sacustep 50) in Pharma Franchise Opportunity in Lucknow

Sacustep 50 Tablet

Composition : Sacubitril 24 mg + Valsartan 26 mg tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10x14

Price : ₹390/-

Please Contact For Best Price

Sacustep 50 Tablet is a prescription medication that combines Sacubitril and Valsartan in a fixed-dose formulation. This combination belongs to a class of drugs known as angiotensin receptor neprilysin inhibitors (ARNIs). Sacubitril is a neprilysin inhibitor that helps increase the levels of beneficial peptides like natriuretic peptides, which promote vasodilation and reduce blood pressure. Valsartan, an angiotensin II receptor blocker (ARB), works by blocking the effects of angiotensin II, a hormone that causes blood vessels to constrict, thereby lowering blood pressure and reducing strain on the heart. Together, they provide a synergistic effect that helps in improving heart function and reducing the risk of cardiovascular events, particularly in patients with chronic heart failure with reduced ejection fraction (HFrEF). Sacustep 50 is formulated to provide effective blood pressure control, reduce hospitalizations, and improve survival in patients suffering from heart failure. It represents a modern and evidence-based approach to the long-term management of heart failure and is typically used as a replacement for ACE inhibitors or ARBs in patients who tolerate it.

Read More

About the Product

Sacustep 50 Tablet is a prescription medication that combines Sacubitril and Valsartan in a fixed-dose formulation. This combination belongs to a class of drugs known as angiotensin receptor neprilysin inhibitors (ARNIs). Sacubitril is a neprilysin inhibitor that helps increase the levels of beneficial peptides like natriuretic peptides, which promote vasodilation and reduce blood pressure. Valsartan, an angiotensin II receptor blocker (ARB), works by blocking the effects of angiotensin II, a hormone that causes blood vessels to constrict, thereby lowering blood pressure and reducing strain on the heart. Together, they provide a synergistic effect that helps in improving heart function and reducing the risk of cardiovascular events, particularly in patients with chronic heart failure with reduced ejection fraction (HFrEF). Sacustep 50 is formulated to provide effective blood pressure control, reduce hospitalizations, and improve survival in patients suffering from heart failure. It represents a modern and evidence-based approach to the long-term management of heart failure and is typically used as a replacement for ACE inhibitors or ARBs in patients who tolerate it.

Some commonly reported side effects of Sacustep 50 Tablet include dizziness, low blood pressure (hypotension), increased potassium levels (hyperkalemia), fatigue, and kidney function impairment. Cough may occur in some cases. A rare but serious side effect is angioedema—swelling of the lips, face, or throat—which requires immediate medical attention. Regular monitoring of blood pressure, kidney function, and electrolyte levels is essential during treatment.

Sacustep 50 Tablet is primarily indicated for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in adult patients. It is prescribed to reduce the risk of cardiovascular death and heart failure-related hospitalizations. The medication is especially beneficial in patients who remain symptomatic despite optimal standard treatment with ACE inhibitors, ARBs, beta-blockers, and diuretics.

Sacustep 50 Tablet should only be used under medical supervision. It must not be used together with ACE inhibitors due to the risk of serious side effects such as angioedema. There should be a washout period of at least 36 hours if switching from an ACE inhibitor. This medication is not recommended during pregnancy or while breastfeeding. Patients with a history of angioedema or severe liver impairment should not take this medication. Always inform your doctor about any other medications or health conditions before starting treatment with Sacustep 50. Regular follow-up and laboratory tests are essential for safe and effective use.

Store Sacustep 50 Tablet in a cool and dry place below 30°C. Keep it away from moisture, direct sunlight, and heat. Ensure the medication is stored out of reach of children and pets. Do not use the tablet past its expiry date. Keep the product in its original packaging until use to protect it from light and humidity.

Get in Touch